{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:44:18Z","timestamp":1790376258186,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,8]]},"DOI":"10.7759\/cureus.96393","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T04:45:41Z","timestamp":1762663541000},"source":"Crossref","is-referenced-by-count":4,"title":["Euglycemic Diabetic Ketoacidosis Associated with Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: A Case Series and Clinical Reflections"],"prefix":"10.7759","author":[{"given":"Atqua","family":"Sultan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mah Noor","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasir","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahrukh","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Danial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38921","article-title":"An unfortunate miss of undiagnosed arterial ischemic stroke (AIS) in the setting of diabetic ketoacidosis in an adult: a case report","volume":"15","author":"Obi MF","year":"2023","unstructured":"Obi MF, Namireddy V, Sharma M, Cho HJ, Udoyeh C, Mor\u00f3n Mercado LC, Htut Hann H. An unfortunate miss of undiagnosed arterial ischemic stroke (AIS) in the setting of diabetic ketoacidosis in an adult: a case report. Cureus. 2023, 15:e38921. 10.7759\/cureus.38921","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.23937\/2474-3674\/1510145","article-title":"Euglycemic diabetic ketoacidosis presentation in association with SGLT-2 inhibitor\u2014dapagliflozin","volume":"8","author":"Vettikkat LJ","year":"2022","unstructured":"Vettikkat LJ, Paramba YVC. Euglycemic diabetic ketoacidosis presentation in association with SGLT-2 inhibitor\u2014dapagliflozin. Int J Crit Care Emerg Med. 2022, 8:145. 10.23937\/2474-3674\/1510145","journal-title":"Int J Crit Care Emerg Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-19-0087","article-title":"Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis","volume":"2019","author":"Rafey MF","year":"2019","unstructured":"Rafey MF, Butt A, Coffey B, Reddington L, Devitt A, Lappin D, Finucane FM. Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis. Endocrinol Diabetes Metab Case Rep. 2019, 2019:10.1530\/EDM-19-0087","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-Sint","article-title":"Introduction: standards of medical care in diabetes-2022","volume":"45","year":"2022","unstructured":"Introduction. standards of medical care in diabetes-2022. Diabetes Care. 2022, 45:S1-2. 10.2337\/dc22-Sint","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2017.1370371","article-title":"The effect of SGLT2 inhibitors on cardiovascular events and renal function","volume":"10","author":"Imprialos KP","year":"2017","unstructured":"Imprialos KP, Stavropoulos K, Doumas M, Karagiannis A, Athyros VG. The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Rev Clin Pharmacol. 2017, 10:1251-61. 10.1080\/17512433.2017.1370371","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019, 393:31-9. 10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.03.014","article-title":"Euglycemic diabetic ketoacidosis","volume":"63","author":"Barski L","year":"2019","unstructured":"Barski L, Eshkoli T, Brandstaetter E, Jotkowitz A. Euglycemic diabetic ketoacidosis. Eur J Intern Med. 2019, 63:9-14. 10.1016\/j.ejim.2019.03.014","journal-title":"Eur J Intern Med"},{"key":"ref8","unstructured":"U.S. Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. FDA Drug Safety Communication. (2015). https.\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1081\/erc-120018678","article-title":"Diabetic ketoacidosis promotes a prothrombotic state","volume":"29","author":"Carl GF","year":"2003","unstructured":"Carl GF, Hoffman WH, Passmore GG, Truemper EJ, Lightsey AL, Cornwell PE, Jonah MH. Diabetic ketoacidosis promotes a prothrombotic state. Endocr Res. 2003, 29:73-82. 10.1081\/erc-120018678","journal-title":"Endocr Res"},{"key":"ref10","article-title":"Diabetic ketoacidosis induced by SGLT2 inhibitors in acute ischemic stroke: a report of two cases","volume":"17","author":"Jeong J-H","unstructured":"Jeong J-H. Diabetic ketoacidosis induced by SGLT2 inhibitors in acute ischemic stroke: a report of two cases. J Neurocrit Care. 17:98-101.","journal-title":"J Neurocrit Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16385","article-title":"A review of the safety of sodium-glucose co-transporter-2 inhibitors","volume":"27","author":"O'Hara DV","year":"2025","unstructured":"O'Hara DV, Jardine MJ. A review of the safety of sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2025, 27:3598-606. 10.1111\/dom.16385","journal-title":"Diabetes Obes Metab"},{"key":"ref12","article-title":"SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness","volume":"13","author":"Medicines and Healthcare products Regulatory Agency (MHRA)","year":"2020","unstructured":"Medicines and Healthcare products Regulatory Agency (MHRA). SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness. Drug Safety Update. 2020, 13:8.","journal-title":"Drug Safety Update"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/433609-euglycemic-diabetic-ketoacidosis-associated-with-sodium-glucose-cotransporter-2-sglt2-inhibitors-a-case-series-and-clinical-reflections","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T04:45:44Z","timestamp":1762663544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/433609-euglycemic-diabetic-ketoacidosis-associated-with-sodium-glucose-cotransporter-2-sglt2-inhibitors-a-case-series-and-clinical-reflections"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.96393","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,8]]}}}